Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBIT (2017 - 2025)

Dianthus Therapeutics has reported EBIT over the past 8 years, most recently at -$40.3 million for Q3 2025.

  • Quarterly results put EBIT at -$40.3 million for Q3 2025, down 34.74% from a year ago — trailing twelve months through Sep 2025 was -$140.3 million (down 69.24% YoY), and the annual figure for FY2024 was -$101.9 million, down 111.45%.
  • EBIT for Q3 2025 was -$40.3 million at Dianthus Therapeutics, down from -$34.9 million in the prior quarter.
  • Over the last five years, EBIT for DNTH hit a ceiling of $29.9 million in Q4 2022 and a floor of -$40.3 million in Q3 2025.
  • Median EBIT over the past 4 years was -$18.1 million (2022), compared with a mean of -$18.6 million.
  • Biggest five-year swings in EBIT: soared 67.76% in 2023 and later crashed 146.34% in 2024.
  • Dianthus Therapeutics' EBIT stood at $29.9 million in 2022, then tumbled by 143.28% to -$13.0 million in 2023, then crashed by 146.34% to -$31.9 million in 2024, then decreased by 26.23% to -$40.3 million in 2025.
  • The last three reported values for EBIT were -$40.3 million (Q3 2025), -$34.9 million (Q2 2025), and -$33.2 million (Q1 2025) per Business Quant data.